Core Viewpoint - The law firm Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Stride, Inc. for alleged violations of the Securities Exchange Act of 1934, involving misleading statements and non-disclosure of critical operational issues during the specified class period [1][3]. Summary by Sections Class Action Details - Purchasers or acquirers of Stride, Inc. securities from October 22, 2024, to October 28, 2025, have until January 12, 2026, to seek lead plaintiff status in the class action lawsuit [1]. - The lawsuit is titled MacMahon v. Stride, Inc., No. 25-cv-02019 (E.D. Va.) [1]. Allegations Against Stride - The lawsuit alleges that Stride inflated enrollment numbers by retaining "ghost students," cut staffing costs by overloading teachers, ignored compliance requirements, suppressed whistleblowers, and lost existing and potential enrollments [3]. - A complaint filed by the Gallup-McKinley County Schools Board of Education against Stride included allegations of fraud and deceptive practices, which led to a nearly 12% drop in Stride's stock price [4]. - Following a report on poor customer experience leading to higher withdrawal rates and lower conversion rates, Stride estimated a loss of 10,000-15,000 enrollments, resulting in a more than 54% decline in stock price [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Stride securities during the class period to seek lead plaintiff status, which enables them to act on behalf of other class members [6]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7].

Core Viewpoint - A class action lawsuit has been filed on behalf of shareholders of Gauzy Ltd. due to alleged securities fraud during the specified class period from March 11, 2025, to November 13, 2025 [1] Group 1: Company Developments - On November 14, 2025, Gauzy announced the initiation of French law insolvency proceedings for three of its subsidiaries in France, aimed at preserving business operations and repaying creditors [3] - The commencement of these insolvency proceedings constitutes a default under the Company's existing senior secured debt facilities, which could lead to further financial complications if not addressed [3] - The Company will not release its third-quarter financial results as previously scheduled due to the ongoing insolvency proceedings [3] Group 2: Market Reaction - Following the announcement of insolvency proceedings, Gauzy's share price dropped by $2.00, or 49.8%, over two trading days, closing at $2.02 per share on November 17, 2025, with unusually high trading volume [4] Group 3: Lawsuit Details - The class action lawsuit alleges that during the class period, the defendants made materially false and misleading statements and failed to disclose critical adverse facts about the Company's financial health and operations [5] - Specific allegations include the failure to disclose that three French subsidiaries were unable to meet their debts, the likelihood of insolvency proceedings, and the potential triggering of defaults under senior secured debt facilities [5]

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique structure does not provide superior clinical benefits [2]. - Allegations include that SLK's supposed increased tissue penetration does not translate to clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Law Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years, highlighting its expertise in complex securities cases [4].

NEW YORK, Dec. 9, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Synopsys, Inc. ("Synopsys, Inc." or the "Company") (NASDAQ: SNPS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Synopsys, Inc. investors who were adversely affected by alleged securities fraud between December 4, 2024 and September 9, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/synopsys-inc-law ...

NEW YORK, Dec. 9, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in StubHub Holdings, Inc. ("StubHub Holdings, Inc." or the "Company") (NYSE: STUB) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of StubHub Holdings, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons and entities that purchased or otherwise acquired StubHub common stock pursuant and/or traceable to the registration ...

Core Viewpoint - A class action securities lawsuit has been filed against CarMax, Inc. alleging securities fraud that affected investors between June 20, 2025, and November 5, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that defendants made false statements regarding CarMax's growth prospects, suggesting that earlier growth was a temporary benefit due to customer speculation about tariffs [2]. - It is alleged that the statements made by defendants about CarMax's business operations and prospects were materially false and misleading, lacking a reasonable basis [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until January 2, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the poor launch of its new product, Inspire V, which was marked by significant operational failures and misrepresentations to investors [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged securities fraud between August 6, 2024, and August 4, 2025 [1]. - Defendants are accused of making false statements regarding the successful launch of Inspire V, while in reality, demand was low and providers had excess inventory [2]. - Key operational failures included inadequate training for treatment center customers, unestablished IT systems, and lack of Medicare reimbursement at launch [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until January 5, 2026, to request appointment as lead plaintiff, although participation in recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action securities lawsuit has been filed against Avantor, Inc. alleging securities fraud that negatively impacted investors between March 5, 2024, and October 28, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Avantor's competitive positioning was misrepresented, indicating it was weaker than publicly stated [2]. - It is alleged that Avantor faced negative impacts from increased competition, which were not disclosed by the defendants [2]. - The representations made by the defendants regarding the company's business, operations, and prospects are claimed to be materially false and misleading [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 29, 2025, to request appointment as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the United States [4].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with its latest product being the Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, while in reality, the company failed to prepare clinicians and payors adequately, leading to delays in adoption and weak demand [5][6]. - The company faced challenges such as implanting centers not completing required training and software updates for claims processing not being effective until July 1, 2025, which hindered billing for procedures [7]. Stock Performance - Following the announcement of an "elongated timeframe" for the Inspire V launch and a reduction in 2025 earnings per share guidance by over 80%, Inspire's stock price plummeted by $42.04, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - A class action lawsuit has been filed against Freeport-McMoRan Inc. and certain senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1][3]. Company Overview - Freeport-McMoRan Inc. is a mining company with its Indonesian affiliate operating as PT Freeport Indonesia, which manages the Grasberg Copper and Gold Mine [4]. Allegations - The lawsuit alleges that Freeport overstated its commitment to safety, as unsafe mining practices at the Grasberg mine were likely to result in worker fatalities [5]. Stock Performance - On September 9, 2025, Freeport's stock dropped by $2.77 per share (over 5.9%) following a press release about suspended mining operations due to a landslide [6]. - On September 24, 2025, after an update on the incident revealed two fatalities and operational suspensions, the stock fell by $7.69 per share (almost 17%) [7]. - On September 25, 2025, reports of strained relations with the Indonesian government led to a further decline of $2.33 per share (over 6%) [8]. - An Indonesian news report on September 28, 2025, indicated that the landslide was preventable, further impacting investor confidence [9].